Diabetes
The 2026 diabetes guidelines back GLP-1 drugs in type 1 diabetes for the first time
For years the diabetes guidelines kept GLP-1 drugs firmly on the type 2 side of the ledger. The 2026 update quietly changes that — and for women with type 1 diabetes, the reasons it matters go beyond the headline.
In its 2026 Standards of Care, the American Diabetes Association (ADA) for the first time endorses GLP-1 receptor agonist–based therapy as an option to manage obesity in adults who have type 1 diabetes (T1D) and a body mass index of 30 or above (27.5 or above for Asian Americans). Bariatric (metabolic) surgery is recommended for the same group. Earlier editions had kept these drugs out of routine type 1 care.
Two things are worth being precise about. First, this is a recommendation for weight and obesity management — not a glucose-lowering swap, and not for everyone with T1D. Insulin remains essential; a GLP-1 would sit on top of it. Second, drugs such as semaglutide and tirzepatide still aren’t licensed specifically for type 1 diabetes, so this is guideline-supported use for the obesity indication, to be weighed drug by drug with your team.
The evidence behind it is real but still modest. The largest trials in T1D used liraglutide 1.8 mg and found only small average effects — roughly a 0.4% drop in HbA1c, about 5 kg of weight loss, and slightly lower insulin doses. Data for the newer, stronger drugs (semaglutide, tirzepatide) in type 1 diabetes so far come from small retrospective series and pilot studies rather than large randomised trials. The guideline also flags the real risks of adding a GLP-1 to insulin — low blood sugar, and a form of diabetic ketoacidosis that can occur even when glucose looks near-normal. Remember, too, that Standards of Care are expert consensus built on pooled evidence, not a single clinical trial.
The 2026 update makes two other changes that quietly help people with T1D: continuous glucose monitoring is now recommended from diagnosis and for anyone who could benefit, with an explicit push to remove insurance barriers; and the prerequisites people previously had to meet to qualify for an automated insulin delivery (‘closed-loop’) system have been dropped to widen access. Together they lower the bar to the tools that smooth out day-to-day control — see my note on reading glucose patterns.
None of this is written specifically for women — but it lands differently for them. Women with T1D ride a monthly tide of insulin sensitivity: in the second half of the cycle (the luteal phase) sensitivity falls, and glucose tends to run higher and more variable. At the other end of the reproductive years, a 2025 Dutch survey of 159 women with T1D found about two-thirds felt their control worsened after menopause, when falling oestrogen adds insulin resistance and visceral weight. An obesity-management tool that also protects the heart, kidneys and liver is therefore squarely relevant to midlife women — with the honest caveat that women have long been under-represented in T1D drug and device trials, so this is a conversation to individualise, not a prescription to assume. If perimenopause is part of your picture, my post on perimenopause and blood sugar goes deeper.
What the research says
Recommendation 8.29 in the ADA’s Standards of Care in Diabetes—2026 supports GLP-1 receptor agonist–based therapy (evidence grade B) and metabolic surgery (grade C) as obesity-management options for adults with type 1 diabetes and a BMI ≥30 kg/m² (≥27.5 for Asian Americans). It is a shift from earlier Standards, which excluded GLP-1s from routine type 1 care on the grounds of limited evidence and safety concerns. The Standards are evidence-graded clinical guidelines, not a single trial.
American Diabetes Association · Standards of Care in Diabetes—2026, Section 8 ↗The largest randomised trials of GLP-1 receptor agonists in type 1 diabetes used liraglutide 1.8 mg daily and showed modest effects — about a 0.4% reduction in HbA1c, roughly 5 kg of weight loss, and small reductions in insulin dose. Evidence for semaglutide and tirzepatide in type 1 diabetes so far comes mainly from small retrospective case series and pilot studies. Adding a GLP-1 to insulin raises the risk of hypoglycaemia and of euglycaemic diabetic ketoacidosis.
diaTribe · Your Guide to the 2026 ADA Standards of Care ↗In a 2025 cross-sectional survey of 159 women with type 1 diabetes in the Netherlands, about two-thirds reported that their blood-glucose regulation felt worse after menopause. Separately, controlled studies show insulin sensitivity falls in the luteal (second) half of the menstrual cycle, raising average glucose and time above range. Both are observational or physiological findings, not treatment trials.
Diabetologia · Cross-sectional survey, 2025 ↗Frequently asked questions
Does this mean people with type 1 diabetes should start a GLP-1 like Ozempic?
Not from the headline alone. The 2026 guideline supports GLP-1s specifically for adults with type 1 diabetes who also have obesity (BMI ≥30), as a way to manage weight alongside insulin — not as a routine addition for everyone with T1D, and not as a glucose treatment in its own right. Whether it fits you depends on your weight, your other health risks and your team’s judgement, because these drugs aren’t licensed for type 1 and add some risk on top of insulin.
Can a GLP-1 replace insulin in type 1 diabetes?
No. Type 1 diabetes means the body makes little or no insulin, so insulin is life-sustaining and can’t be replaced by a GLP-1. In type 1 a GLP-1 is only ever an add-on — here, for managing obesity — and using one alongside insulin needs care, because it can increase the risk of low blood sugar and of ketoacidosis. Never adjust or stop insulin without medical advice.
The information on this website is educational and is not medical advice. Please consult your doctor if you have any doubts or further questions.